Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

This study is testing a combination of three drugs — obinutuzumab, ibrutinib, and venetoclax — as a first treatment for follicular lymphoma (a slow-growing type of blood cancer) without using traditional chemotherapy. **You may be eligible if...** - You have been newly diagnosed with follicular lymphoma (grades 1, 2, or 3a) and have not yet received any treatment - Your lymphoma is measurable on scans and requires treatment - You are 18 or older and in adequate overall health **You may NOT be eligible if...** - Your lymphoma has transformed into a more aggressive type - You have grade 3b follicular lymphoma - You have active lymphoma in the central nervous system or spinal fluid - You have had prior treatment for follicular lymphoma - You have significant heart rhythm problems or are on certain blood thinners Talk to your doctor to see if this trial is right for you.